CATX · Insider Trading
Perspective Therapeutics, Inc.
Every open-market purchase and sale reported by CATX officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-09-08 | Lantheus Holdings, Inc. | 10%+ Owner | Sell | −495,864 | −$1.55M |
| 2026-09-04 | Lantheus Alpha Therapy, LLC | 10%+ Owner | Sell | −84,258 | −$262.44K |
| 2026-09-04 | Lantheus Alpha Therapy, LLC | 10%+ Owner | Sell | −113,914 | −$357.18K |
| 2026-09-03 | Lantheus Holdings, Inc. | 10%+ Owner | Sell | −35,769 | −$111.57K |
| 2026-09-02 | Lantheus Holdings, Inc. | 10%+ Owner | Sell | −78,145 | −$245.61K |
| 2026-03-04 | Frank Morich | Director | A | +50,000 deriv. | — |
| 2026-03-04 | Jonathan Robert Hunt | Chief Accounting Officer | A | +90,000 deriv. | — |
| 2026-03-04 | Lori A Woods | Director | A | +50,000 deriv. | — |
| 2026-03-04 | Markus Puhlmann | Chief Medical Officer | A | +150,000 deriv. | — |
| 2026-03-04 | Johan M. Spoor | Chief Executive Officer | A | +735,000 deriv. | — |
| 2026-03-04 | Heidi Henson | Director | A | +50,000 deriv. | — |
| 2026-03-04 | Robert F Williamson III | Director | A | +50,000 deriv. | — |
| 2026-03-04 | Maria E Martinez | Director | A | +50,000 deriv. | — |
| 2025-11-17 | Jonathan Robert Hunt | Chief Accounting Officer | Buy | +11,000 | +$22.29K |
| 2025-11-14 | Robert F Williamson III | Director | Buy | +9,498 | +$19.95K |
| 2025-09-05 | Joel Sendek | Chief Financial Officer | A | +600,000 deriv. | — |
| 2025-09-05 | Maria E Martinez | Director | A | +75,000 deriv. | — |
| 2025-04-01 | Lori A Woods | Director | Buy | +23,475 | +$50.00K |
| 2025-04-01 | Juan Graham | Chief Financial Officer | Buy | +33,333 | +$74.95K |
| 2025-04-01 | Robert F Williamson III | Director | Buy | +60,337 | +$132.15K |
| 2025-04-01 | Johan M. Spoor | Chief Executive Officer | Buy | +26,676 | +$59.67K |
| 2025-03-05 | Jonathan Robert Hunt | Chief Accounting Officer | A | +75,000 deriv. | — |
| 2025-03-05 | Robert F Williamson III | Director | A | +50,000 deriv. | — |
| 2025-03-05 | Johan M. Spoor | Chief Executive Officer | A | +650,000 deriv. | — |
| 2025-03-05 | Lori A Woods | Director | A | +50,000 deriv. | — |
| 2025-03-05 | Heidi Henson | Director | A | +50,000 deriv. | — |
| 2025-03-05 | Frank Morich | Director | A | +50,000 deriv. | — |
| 2025-03-05 | Markus Puhlmann | Chief Medical Officer | A | +165,000 deriv. | — |
| 2025-01-07 | Juan Graham | Chief Financial Officer | A | +400,000 deriv. | — |
| 2024-12-06 | Heidi Henson | Director | Buy | +25,975 | +$100.00K |
| 2024-12-04 | Robert F Williamson III | Director | — | — | — |
| 2024-12-04 | Johan M. Spoor | CEO | — | — | — |
| 2024-12-04 | Johan M. Spoor | CEO | Buy | +8,000 | +$30.13K |
| 2024-11-27 | Jonathan Robert Hunt | Chief Financial Officer | Buy | +12,829 | +$48.97K |
| 2024-11-27 | Robert F Williamson III | Director | Buy | +6,266 | +$22.81K |
| 2024-11-26 | Johan M. Spoor | CEO | Buy | +26,500 | +$100.47K |
| 2024-07-19 | Mark John Austin | VP Finance/Prin Fin&Acct Offic | A | +34,500 deriv. | — |
| 2024-06-24 | Heidi Henson | Director | A | +23,000 deriv. | — |
| 2024-06-24 | Robert F Williamson III | Director | A | +23,000 deriv. | — |
| 2024-06-24 | Lori A Woods | Director | A | +23,000 deriv. | — |
| 2024-06-24 | Markus Puhlmann | Chief Medical Officer | A | +150,000 deriv. | — |
| 2024-06-24 | Johan M. Spoor | CEO | A | +500,000 deriv. | — |
| 2024-06-24 | Jonathan Robert Hunt | Chief Financial Officer | A | +100,000 deriv. | — |
| 2024-06-24 | Frank Morich | Director | A | +23,000 deriv. | — |
| 2024-06-18 | Lori A Woods | Director | Buy | +4,587 | +$49.99K |
| 2024-06-18 | Jonathan Robert Hunt | Chief Financial Officer | Buy | +1,800 | +$17.67K |
| 2024-06-13 | Johan M. Spoor | CEO | Buy | +100,000 | +$117.43K |
| 2024-06-05 | Lori A Woods | Director | — | — | — |
| 2024-06-04 | Lori A Woods | Director | Buy | +34,246 | +$49.99K |
| 2024-06-03 | Jonathan Robert Hunt | Chief Financial Officer | Buy | +25,006 | +$35.01K |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| Lantheus Alpha Therapy, LLC | 10%+ Owner | 11,599,194 | $26.16M |
| Lantheus Holdings, Inc. | 10%+ Owner | 11,440,513 | $25.80M |
| Lori A Woods | Director | 188,267 | $424.54K |
| Markus Puhlmann | Chief Medical Officer | 137,542 | $310.16K |
| Robert F Williamson III | Director | 118,846 | $268.00K |
| Johan M. Spoor | Chief Executive Officer | 64,783 | $146.09K |
| Jonathan Robert Hunt | Chief Accounting Officer | 59,800 | $134.85K |
| Juan Graham | Chief Financial Officer | 35,354 | $79.72K |
| Heidi Henson | Director | 25,975 | $58.57K |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the CATX quote page; the site-wide leaderboard is on the insider transactions hub.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.